A NEXT-GENERATION FCRL5/BCMA TRISPECIFIC ANTIBODY DEMONSTRATES SUPERIOR ACTIVITY OVER BISPECIFIC CONSTRUCTS AND SUPPORTS CLINICAL DEVELOPMENT IN B-CELL MALIGNANCIES (EHA 2026) - May 12, 2026 - Abstract #EHA-3483; PF1208; Pres time: Jun 12, 2026; 06:45 PM - 07:45 PM; Location: Hall A; "In the disseminated U266 B1 MM model, dose-escalation studies showed that TriTE achieved superior antitumor activity at a 10-fold lower dose than Teclistamab and prolonged survival; median survival: 62 days for control, 82 days for Teclistamab while all TriTE-treated mice remained alive beyond 130 days, consistent with durable responses in this model. . Summary/Conclusion Leveraging a high-throughput discovery platform, we have generated BCMA/FcRL5 TriTE antibodies with superior antitumor activity and increased in vivo potency, outperforming BCMA-directed therapy even at lower doses in vivo. These results support dual-antigen targeting as a strategy to overcome the limitations of BCMA-only approaches and provide a strong rationale for clinical translation of our BCMA/FcRL5 TriTE in MM and WM."
Bispecific • Clinical • IO biomarker • Trispecific • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Multiple Myeloma • Waldenstrom Macroglobulinemia • GPRC5D
|
|
Jessica Encinas Mayoral 1; Jian Cui 1; Alice Mattinson 2; Edward King 2; Yulia Lampi 2; Simon Bornschein 2; Steve Treon 1; Zachary Hunter 1; Mehmet Samur 1; Mariateresa Fulciniti 1; Nikhil Munshi1
|